NewTimeSpace News: On 10 August 2026, MICOT PHARMA-B (02335.HK): Preclinical and Phase I data of the self-developed candidate drug MT200605 for acute ischaemic stroke have been accepted for oral presentation at WSC 2026 (21-23 October, Seoul); MT200605 is the world's only agonist crossing the blood-brain barrier and acting on the BDNF/TrkB pathway that has entered clinical development, and its Phase II trial has met its primary endpoint with statistically significant results.
NewTimeSpace News: On 10 August 2026, GRAPHEX GROUP (06128.HK): The Group's research project EcoFlux has won the 2026 R&D 100 Award; the technology revolutionises natural graphite anode material production and was jointly developed by Graphite Innovation and Technology and ASTRI, controlling anode expansion below 5% and enabling 20-minute fast charging, with two patent applications filed in China and the United States and industrialisation planned as soon as practicable.
NewTimeSpace News: CSPC Pharmaceutical Group announced on 10 August that SYS6037 Injection (monkeypox mRNA vaccine), co‑developed with the Institute of Microbiology, Chinese Academy of Sciences, has been approved by the US FDA for clinical trials.
On August 10, 2026, the three major indices collectively strengthened, with the Hang Seng Index rising 1.05%, the Hang Seng Tech Index gaining 1.26%, and the Hang Seng China Enterprises Index advancing 1.06%.The autonomous driving sector performed actively. WERIDE-W (00800.HK) rose 5.45%, PONY-W (02026.HK) gained 3.67%, while HORIZONROBOT-W and ROBOSENSE followed higher. BLACK SESAME (02533.HK) fell 2.02%.
NewTimeSpace News:August 10, 2026,XPENG-W (09868.HK) rose modestly in afternoon trading, quoted at HK$47.04 as of 15:40, up 0.86%.
NewTimeSpace (newtimespace.com) reported that on August 10, 2026, the robotics theme weakened, while Xiaomi-W (01810.HK) fluctuated higher. As of 13:35, the stock was quoted at HKD 27.440, up 1.40%.
NewTimeSpace (newtimespace.com) reported that on August 10, 2026, the semiconductor theme in Hong Kong stocks weakened, with ASMPT (00522.HK) fluctuating slightly lower. As of 13:23, the stock was quoted at HKD 160.700, down 0.56%.
NewTimeSpace News: On 10 August 2026, KEYMED BIO-B (02162.HK): The Phase II clinical trial of self-developed CM512 (TSLP x IL-13 bispecific antibody) for chronic rhinosinusitis with nasal polyps met all study endpoints, with comparable efficacy and a favourable safety profile across dose groups and single-dose efficacy lasting six months; the Company is rapidly initiating Phase III with the 300mg Q24W regimen, and the drug was included in the Breakthrough Therapy Designation list by the CDE of the NMPA on 23 July.
NewTimeSpace News: On 10 August 2026, GENFLEET-B (02595.HK): The oral KRAS G12D inhibitor GFH375 has entered a registrational Phase III study (the "Qilin-Fei 01") in China as monotherapy for NSCLC, being its second registrational clinical study, with the first patient enrolled at Nanjing Drum Tower Hospital; GFH375 has obtained two BTDs for NSCLC and pancreatic cancer this year, with the latest monotherapy later-line data to be presented as an oral presentation at this year's WCLC.
NewTimeSpace News: LUZHU BIOTECH-B (02480.HK) announced that the Phase III results of its core product LZ901 in China were published in Nature Communications: overall vaccine efficacy of 91.6% within one year (95% CI: 86.3%–95.3%), 92.1% against laboratory-confirmed cases and 95.9% against postherpetic neuralgia, with 26,039 subjects enrolled and 25,577 vaccinated; the BLA is currently under review by the NMPA.
On 7 August, Hong Kong stocks opened lower and closed higher, with the Hang Seng TECH Index up 0.78%. The twin large-model titans Z.AI surged 14.6% and MINIMAX-W jumped 9.8%, having once accumulated gains of over 30% within two days of joining the Connect; DeepSeek announced a comprehensive increase in API prices, accelerating the convergence of low-price competition in the industry. The AI hardware chain extended its strength, with Goldman Sachs sharply raising its AI server PCB market forecast and GIGADEVICE receiving a RMB 466 million holding increase from Ge Weidong. On the news front, Unitree's IPO was priced at RMB 150.8 per share with DeepSeek and Tencent participating in the strategic placement; Alibaba's Wan 3.0 entered public beta; Zhang Yiming set an internal tone for ByteDance Seed to strictly prohibit distillation; and Meta admitted its AI model intruded into another company during testing, bringing the AI security topic back into focus.
NewTimeSpace News: On 7 August 2026, BIDU-SW (09888.HK) slipped slightly in the afternoon. As at 15:26, the stock was quoted at HK$106.80, down 0.28%. In June this year, Apollo Go claimed the top spot with a score of 81.7 in the Robotaxi ranking released by overseas institution Autonomy AI.
NewTimeSpace News: CARSGEN-B (02171.HK): The universal CAR-T product CT1190B targeting CD19/CD20 has received IND approval from the NMPA for the treatment of patients with R/R LBCL who have failed at least two lines of standard therapy; the product was developed on the THANK-u Plus platform, with IIT results presented as a poster at the 2026 EHA annual meeting.
NewTimeSpace News: TRANSTHERA-B announced that its self-developed Class 1 new drug Jientai (tiengotinib tablets) has received conditional NMPA approval for marketing, for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements in patients previously treated with systemic therapy and FGFR inhibitors; the Phase II pivotal study showed an ORR of 28.0% and median overall survival of 20.7 months; the drug has received US FDA Orphan Drug Designation and Fast Track Designation and European EMA Orphan Drug Designation, and this is its first indication approved in China.
NewTimeSpace News: HENGRUI PHARMA announced that the third indication of its subsidiary Suzhou Shengdiya's trastuzumab rezetecan for injection has been approved for marketing, for adult patients with HER2-positive colorectal cancer who failed oxaliplatin, fluorouracil and irinotecan, making it the first anti-HER2 product approved for colorectal cancer in China; the self-developed HER2 ADC has its pivotal Phase III data presented at the 2026 ASCO Annual Meeting, 11 indications included in the Breakthrough Therapy Designation list, and cumulative R&D investment of approximately RMB 2.144 billion.
NewTimeSpace News: HENGRUI PHARMA announced that the NMPA has approved a fifth indication for its self-developed Class 1 innovative drug ivarmacitinib sulfate tablets, for adult patients with active non-radiographic axial spondyloarthritis, achieving full-disease-spectrum oral targeted management coverage of axial spondyloarthritis; the product is a highly selective JAK1 inhibitor with pivotal Phase III data presented at the 2026 EULAR Annual Meeting, and cumulative R&D investment of approximately RMB 1.235 billion.
